SCHEMBL5756907

SCHEMBL5756907

O=P(O)(O)C(Cc1ccccc1)NS(=O)(=O)c1ccc2nc(SCC3CCCCC3)sc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HSP90AA1 P07900 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
MAOB P27338 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GFER P55789 1/20 0.37
CNR1 P21554 1/20 0.37
MAPT P10636 6/20 0.37
CCR1 P32246 1/20 0.36
CCR3 P51677 1/20 0.36
TP53 P04637 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2C9 P11712 1/20 0.36
KMT2A Q03164 1/20 0.36
CLK1 P49759 1/20 0.35
CTSK P43235 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753860 0.88 LMNA (0.43) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5755972 0.87 POLB (0.48) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5755993 0.85 MMP2 (0.48) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5756885 0.82 MAPT (0.44) LMNAALDH1A1SMN1; SMN2GFERMAPT
SCHEMBL5757042 0.81 PPARA (0.46) LMNAALDH1A1SMN1; SMN2GFERMAPT
SCHEMBL5757831 0.80 SMN1; SMN2 (0.51) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5757798 0.80 LMNA (0.52) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5755212 0.79 ALDH1A1 (0.51) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5760231 0.78 ALDH1A1 (0.38) LMNAALDH1A1HSP90AA1HPGDTSHR
SCHEMBL5756642 0.77 SMN1; SMN2 (0.50) LMNAALDH1A1HSP90AA1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 LMNA 1839/4885ALDH1A1 311/4885HSP90AA1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.